On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025
Second Antibody Drug Conjugate Is Next Milestone
Executive Summary
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.
You may also be interested in...
Pfizer’s Talzenna Takes On Top Dog Lynparza In Prostate Cancer
Top-line Phase III results for Talzenna/Xtandi showed improved PFS in mCRPC patients regardless of HRR mutation status, where AstraZeneca/Merck have developed fellow PARP inhibitor Lynparza.
AstraZeneca Hopes Danicopan Interim Data Will Prove Sufficient For NDA Filing
Danicopan seen as potential add-on therapy for paroxysmal nocturnal hemoglobinuria patients getting suboptimal results from Soliris or Ultomiris therapy. AstraZeneca will investigate filing for approval on 12-week data.
Europe’s Big Pharma Sails On Serenely Despite Choppy Economic Waters
The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.